Senior biostatistician and methodologist with over 15 years of experience in clinical trial design, adaptive and precision medicine methodology, and AI for health.
Dr Deepak Parashar (Founder, MedStats AI) is a biostatistician and AI researcher with over 16 years' experience spanning drug development, cancer trial methodology, and precision medicine. Trained at the Cambridge Cancer Trials Centre, he went on to serve as Senior Statistician at the CRUK Cambridge Institute, Associate Professor in Systems Biology and Oncology at the University of Warwick, and most recently as Deputy Lead of the Turing–Roche Partnership at The Alan Turing Institute (2024–2026). He now consults independently as Founder of MedStats AI, and holds a Visiting Professorship of Biostatistics in the Department of Biostatistics, Bioinformatics & Biomathematics at Georgetown University, Washington DC, alongside a Visiting Researcher role at the MRC Biostatistics Unit, Cambridge. He has been lead statistician on over 15 cancer clinical trials and has led industrial collaborations with Roche and AstraZeneca on machine learning and biomarker-guided decision frameworks.
Peer-reviewed publications in Nature Machine Intelligence, Pharmaceutical Statistics, Annals of Oncology, and more
Research funding secured as PI and co-investigator, including MRC, NIHR, Royal Society, and Wellcome Trust
Drug development statistics, adaptive trial design, and AI for precision medicine across academia, NHS, and pharma
Clinical Trial Methodology
Adaptive and enrichment designs, biomarker-stratified trials, master protocols (basket, umbrella, platform), type I error control, sample size and power, Simon two-stage designs, regulatory statistics aligned with ICH E9(R1) and FDA/EMA guidance.
Health AI & Precision Medicine
Machine learning for patient stratification, personalised uncertainty quantification, AI assurance and governance, multimodal AI for oncology, real-world evidence and decision modelling.
Available for consulting engagements in clinical trial statistics, adaptive design, AI for health, and regulatory methodology. Also available for expert witness, grant review panels, and advisory board roles.